Literature DB >> 19793383

Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Irit Avivi1, Silvia Montoto, Carme Canals, John Maertens, Haifa Al-Ali, Ghulam J Mufti, Jürgen Finke, Anton Schattenberg, Renato Fanin, Jan J Cornelissen, Jean-Paul Vernant, Nigell Russell, Yves Beguin, Kirsty Thomson, Leo F Verdonck, Guido Kobbe, Herve Tilly, Gerard Socié, Anna Sureda.   

Abstract

Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the outcome of patients with FL treated with MUD-SCT included in the European Group for Blood and Marrow Transplantation registry. 131 patients treated with reduced-intensity conditioning (RIC, n = 87) or conventional myeloablative (CONV, n = 44) MUD-SCT between 2000 and 2005 were included. Median time from diagnosis to MUD-SCT was 47 months and the median number of previous therapeutic regimens was 4 (previous autograft: 47%). RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) was 24% and 30% at 100-d and 1-year, respectively. After a median follow-up of 36 months, 17% of the patients developed disease progression, the 3-year progression-free survival (PFS) being 47%. Three-year overall survival (OS) for the whole series was 51%. On multivariate analysis, RIC regimens were associated with at lower NRM and a significantly longer PFS and OS. This retrospective study demonstrated that MUD-SCT results, even in heavily pre-treated populations, in a meaningful PFS and OS.

Entities:  

Mesh:

Year:  2009        PMID: 19793383     DOI: 10.1111/j.1365-2141.2009.07905.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 2.  Allogeneic stem cell transplantation in follicular lymphoma.

Authors:  Issa F Khouri
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

Review 3.  Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

Authors:  M A Kharfan-Dabaja; N El-Jurdi; E Ayala; A S Kanate; B N Savani; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

4.  A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.

Authors:  Craig S Sauter; Juliet N Barker; Lauren Lechner; Junting Zheng; Sean M Devlin; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; Jenna D Goldberg; Guenther Koehne; Izaskun Ceberio; Sergio Giralt; Andrew D Zelenetz; Craig H Moskowitz; Hugo Castro-Malaspina
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

5.  Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.

Authors:  F Heinzelmann; W Bethge; D W Beelen; M Engelhard; N Kröger; P Dreger; D Niederwieser; J Finke; D Bunjes; J Tischer; G Kobbe; E Holler; M Bornhäuser; M Stelljes; H Baurmann; A Müller; I Haubitz; H Schrezenmeier; C Müller; H Ottinger
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

6.  Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.

Authors:  Thomas Shea; Jeffrey Johnson; Peter Westervelt; Sherif Farag; John McCarty; Asad Bashey; Luis Isola; Lee-Anne Baxter-Lowe; Michael Kelly; Kouros Owzar; Charles Linker
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-03       Impact factor: 5.742

7.  A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.

Authors:  Craig S Sauter; Joanne F Chou; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; James W Young; Michael Scordo; Sergio Giralt; Hugo Castro-Malaspina
Journal:  Leuk Lymphoma       Date:  2014-03-20

8.  Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-09-17       Impact factor: 2.490

9.  Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.

Authors:  I Avivi; C Canals; J-P Vernant; G Wulf; A Nagler; O Hermine; E Petersen; I Yakoub-Agha; C Craddock; A Schattenberg; D Niederwieser; K Thomson; D Blaise; M Attal; M Pfreundschuh; J Passweg; N Russell; P Dreger; A Sureda
Journal:  Bone Marrow Transplant       Date:  2014-02-10       Impact factor: 5.483

10.  Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Ginna G Laport; Juan Wu; Brent Logan; Veronika Bachanova; Chitra Hosing; Timothy Fenske; Walter Longo; Steven M Devine; Auayporn Nademanee; Iris Gersten; Mary Horowitz; Hillard M Lazarus; Marcie L Riches
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-23       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.